Mark Robson

Mark Robson at Memorial Sloan Kettering is a leading expert in hereditary breast and ovarian cancer syndromes and germline BRCA-related clinical management. He led the OlympiAD trial demonstrating olaparib efficacy in germline BRCA-mutated HER2-negative breast cancer, leading to FDA approval. His clinical research covers BRCA risk assessment, risk-reducing interventions, and emerging therapeutic options for hereditary breast cancer.